Share Price | Treace Medical Concepts, Inc. Stock Analysis & Recommendation

Q: How big is Treace Medical Concepts, Inc.?

Market Cap: As of Jun 18, Treace Medical Concepts, Inc. has a market capitalization of 342.20 million, categorized as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Treace Medical Concepts, Inc. reported net sales of 210.82 million and a net profit of -52.99 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 112.89 million and total assets of 217.09 million.

Q: What does Treace Medical Concepts, Inc. do?

Overview:Treace Medical Concepts, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 53 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) Market-cap: USD 342.20 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.20 Return on Equity: -50.25% Price to Book: 3.25Contact Details:Registrar Address: Not available.

Q: Should I buy, sell or hold Treace Medical Concepts, Inc.?

Based on the current situation of Treace Medical Concepts, Inc., it would be advisable to hold your position in the stock for now. The company has shown flat results recently, and its debt-equity ratio is notably high at -6.38%, indicating potential financial instability. Additionally, the debtors turnover ratio is at its lowest, which could signal challenges in collecting receivables.The stock is considered risky, particularly since it has a negative EBITDA, and while it has generated a 0% return over the past year, profits have only increased by 2.9%. However, the high institutional holdings at 92.31% suggest that knowledgeable investors are backing the company, which could provide some reassurance.Given these factors, holding seems to be the most prudent course of action until there are clearer signs of improvement or stability in the company's performance.

Q: Is Treace Medical Concepts, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Treace Medical Concepts, Inc. has changed from sideways to mildly bearish. The weekly MACD and KST are mildly bullish, but the monthly MACD and Bollinger Bands indicate a bearish stance. The daily moving averages are mildly bearish, and the weekly OBV is also mildly bearish. Overall, the indicators present a mixed picture, with a bearish bias prevailing in the longer-term metrics.In terms of performance, the stock has underperformed the S&P 500 year-to-date, with a return of -3.36% compared to the S&P's 12.22%. However, over the past year, Treace has outperformed the index with a return of 31.2% versus 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.38 M

Shareholding (Sep 2025)

FII

6.40%

Held by 65 FIIs

DII

72.05%

Held by 26 DIIs

Promoter

0.58%

How big is Treace Medical Concepts, Inc.?

22-Jun-2025

As of Jun 18, Treace Medical Concepts, Inc. has a market capitalization of 342.20 million and reported net sales of 210.82 million with a net profit of -52.99 million over the latest four quarters.

View full answer

What does Treace Medical Concepts, Inc. do?

22-Jun-2025

Treace Medical Concepts, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $53 million and a net loss of $16 million as of March 2025. The company has a market cap of $342.20 million and does not pay dividends.

View full answer

Should I buy, sell or hold Treace Medical Concepts, Inc.?

22-Jun-2025

Is Treace Medical Concepts, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Treace Medical Concepts, Inc. shows a mildly bearish trend with mixed indicators, underperforming the S&P 500 year-to-date at -3.36% but outperforming it over the past year with a return of 31.2%.

View full answer

Compare Treace Medical Concepts, Inc. with Similar Stocks

The Beauty Health Co.Embecta Corp.SI-BONE, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Positive results in Sep 25

OPERATING CASH FLOW(Y) Highest at USD -12.15 MM
NET PROFIT(HY) Higher at USD -33.69 MM
RAW MATERIAL COST(Y) Fallen by 1.35% (YoY)

Risky -

High Institutional Holdings at 86.4%

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 120 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.00

Return on Equity

-56.12%

Price to Book

1.35

Revenue and Profits:

Net Sales:

50 Million

(Quarterly Results - Sep 2025)

Net Profit:

-16 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-44.85%

6 Months

-77.63%

1 Year

-81.82%

2 Years

-88.46%

3 Years

-92.3%

4 Years

-92.09%

5 Years

0.0%

Treace Medical Concepts, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

34.35%

EBIT Growth (5y)

-315.82%

EBIT to Interest (avg)

-7.01

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.20

Sales to Capital Employed (avg)

1.17

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

86.40%

ROCE (avg)

1.06%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.40

EV to EBIT

-8.71

EV to EBITDA

-10.84

EV to Capital Employed

4.91

EV to Sales

1.95

PEG Ratio

Dividend Yield

ROCE (Latest)

-56.36%

ROE (Latest)

-50.33%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 42 Schemes (20.97%)

Foreign Institutions

Held by 65 Foreign Institutions (6.4%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 11.31% vs 10.54% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -5.84% vs 12.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "50.20",
          "val2": "45.10",
          "chgp": "11.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.90",
          "val2": "-13.00",
          "chgp": "0.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.30",
          "val2": "-15.40",
          "chgp": "-5.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-312.20%",
          "val2": "-335.70%",
          "chgp": "2.35%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 11.92% vs 31.95% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -12.53% vs -15.65% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "209.40",
          "val2": "187.10",
          "chgp": "11.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-47.30",
          "val2": "-46.10",
          "chgp": "-2.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.30",
          "val2": "5.20",
          "chgp": "1.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-55.70",
          "val2": "-49.50",
          "chgp": "-12.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-266.00%",
          "val2": "-274.80%",
          "chgp": "0.88%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

50.20

45.10

11.31%

Operating Profit (PBDIT) excl Other Income

-12.90

-13.00

0.77%

Interest

1.30

Exceptional Items

0.00

Consolidate Net Profit

-16.30

-15.40

-5.84%

Operating Profit Margin (Excl OI)

-312.20%

-335.70%

2.35%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 11.31% vs 10.54% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -5.84% vs 12.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

209.40

187.10

11.92%

Operating Profit (PBDIT) excl Other Income

-47.30

-46.10

-2.60%

Interest

5.30

5.20

1.92%

Exceptional Items

-0.10

-0.20

50.00%

Consolidate Net Profit

-55.70

-49.50

-12.53%

Operating Profit Margin (Excl OI)

-266.00%

-274.80%

0.88%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 11.92% vs 31.95% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -12.53% vs -15.65% in Dec 2023

All Annual Results

Company CV

About Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available